Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Phase 3 Completed
239 enrolled 38 charts
Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer
Phase 3 Completed
206 enrolled
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
Phase 3 Completed
1,386 enrolled
Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
Phase 3 Completed
378 enrolled
Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer
Phase 3 Completed
397 enrolled 11 charts
Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
Phase 3 Completed
67 enrolled
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
Phase 3 Completed
21 enrolled
Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
Phase 3 Completed
361 enrolled
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
Phase 3 Completed
306 enrolled
Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
Phase 3 Completed
2,028 enrolled 15 charts
Radiation Therapy and Hormone Therapy in Treating Patients With Prostate Cancer
Phase 3 Completed
1,322 enrolled
Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma
Phase 3 Completed
311 enrolled
Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0 Prostate Cancer
Phase 3 Completed
273 enrolled
Goserelin, Flutamine, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
Phase 3 Completed
Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer
Phase 3 Completed